在癌症中准BATF家族:瘤内在信号和免疫微环境重编程
Siyu Chen1, Yikang Zhao2, Daopeng Chen1
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China; Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.
Cellular signalling
|November 14, 2025
概括
基本的氨酸拉链ATF类转录因子 (BATF) 家族调节瘤免疫力和瘤微环境. 针对BATF提供了新的癌症治疗和生物标志物的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 基本的氨酸拉链ATF类转录因子 (BATF) 家族,包括BATF,BATF2和BATF3,是关键的转录因子.
- 这个家族是免疫细胞功能不可或缺的组成部分,如增殖,分化和耗尽.
- BATF家族成员与瘤免疫微环境有着强烈的关联.
研究的目的:
- 审查BATF家族在瘤微环境中的各种信号通路和细胞因子中的调节作用.
- 探索BATF家族在瘤发育,进展,入侵和转移中的参与.
- 讨论针对BATF家族用于癌症治疗的治疗潜力.
主要方法:
- 对生物反应中BATF家族功能研究的文献综述.
- 在瘤微环境的背景下,BATF调节的信号通路和细胞因子的分析.
- 对BATF家族在瘤免疫力中的作用和潜在的治疗策略的现有研究进行评估.
主要成果:
- 该BATF家族显著影响瘤微环境中的免疫细胞行为.
- BATF家族成员调节关键通路和细胞因子,这些细胞因子与瘤生长和扩散有关.
- 有证据表明,BATF家族与瘤发生,扩散,入侵和转移有关.
结论:
- 该BATF家族是瘤免疫力的关键调节者.
- 准BATF家族为开发新的癌症疗法提供了一个有希望的途径.
- 该BATF家族具有作为癌症诊断或预后生物标志物的潜力.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


